Overview

Diabetic Neuropathic Pain Relief, 6 Weeks Dosage Sublingual Water-soluble CBD/PEA

Status:
Not yet recruiting

Trial end date:
2023-12-05

Target enrollment:

Participant gender:

Summary

The purpose of the study is to evaluate whether the DIA/NPR-6 is a better pain reliever in patients with diabetic neuropathic pain of the feet compared to placebo.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Pure Green Pharmaceuticals Inc.